Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Dusseldorf - Delayed Quote EUR

Syntara Ltd (UUDA.DU)

0.0210

-0.0040

(-16.00%)

At close: April 4 at 7:30:44 PM GMT+2

Syntara announces positive interim data in Phase 2 study of SNT-5505 in myelofibrosis

Syntara Limited (ASX:SNT), a clinical-stage drug development company, is pleased to announce positive interim data from its ongoing Phase 2 clinical trial evaluating SNT-5505 (200 mg BID) in combination with ruxolitinib (RUX) for the treatment of myelofibrosis (MF)1. The interim results2 suggest that SNT-5505 has potential as a breakthrough therapy for MF and are being presented today at the 66th American Society of Hematology annual meeting (ASH). Further interim data will be released in 1H 202

PR Newswire 3 months ago

SNT.AX
The 22% return this week takes Syntara's (ASX:SNT) shareholders one-year gains to 87%

Passive investing in index funds can generate returns that roughly match the overall market. But if you pick the right...

Simply Wall St. 4 months ago

SNT.AX

Performance Overview

Return	UUDA.DU	S&P/ASX 200 [XJO] (^AXJO)
YTD	-52.27%	-6.02%
1-Year	+223.08%	-1.36%
3-Year	-63.48%	+2.05%